Wrinkle appearance: a combined cosmetic patch
Study
Scope of investigation or explicitly identified community interest; not an established indication.2
Skin & hair
SNAP-8
Acetyl octapeptide-3 in cosmetic formulations
Investigational; this profile does not establish an approved use.
What does it do?
Amino-acid sequence
- Glu
- Glu
- Met
- Gln
- Arg
- Arg
- Ala
- Asp
8 residues · N → C14
Reference identity · not independently confirmed14
Length8 amino acids
Molecular weight · Da1,075.16 Da
Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2Identity reported by Pep-Pedia; exact-product sequence and modifications have not been independently confirmed.
Sequence and formulation must be confirmed for the exact material; similarly named products are not necessarily interchangeable.
Pharmacokinetics
Reported half-lifeHuman kinetics not established2
No numerical human elimination estimate is assigned from animal experiments, related molecules, or an unsupported website estimate.
No numerical estimate was found in the checked data or Pep-Pedia profile. A curve would require an unsupported assumption.
What to expect
Study outcomes
Scope of evidence
The peptide’s independent contribution was not isolated in the verified trial.2
Reported timelines
Reference & communitySource expectations
Little change week 1; fine lines 2–3 weeks; visible effects 4–8; claimed fading 2–4 weeks after stopping.14
These are reported timelines, not a prediction of your response.
Doses & schedules
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| TopicalTopical microneedle patch | Multi-ingredient patch; isolated peptide dose not stated in abstract | Overnight application; detailed frequency not stated in abstract | Periocular cosmetic outcomes24 healthy participantsHuman study | 28 days | 2 |
Population 24 healthy participants Context Results apply to the combined formulation. | |||||
| TopicalTopical serum/cream | 3-5% concentration | 2x daily | General Anti-AgingReference report | Continuous use - effects require ongoing application | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. “Up to 63%” is not a typical expected result. Pairing/timing labels are not universal formulation rules. Source tabs Topical | |||||
| OtherTargeted application | 5-10% concentration | 2x daily | Intensive Wrinkle TreatmentReference report | Continuous use - effects require ongoing application | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. “Up to 63%” is not a typical expected result. Pairing/timing labels are not universal formulation rules. Source tabs Topical | |||||
| OtherEye cream/serum | 3-5% concentration | 2x daily | Eye Area TreatmentReference report | Continuous use - effects require ongoing application | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. “Up to 63%” is not a typical expected result. Pairing/timing labels are not universal formulation rules. Source tabs Topical | |||||
| OtherDirect application | 5-10% concentration | 2x daily | Forehead LinesReference report | Continuous use - effects require ongoing application | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. “Up to 63%” is not a typical expected result. Pairing/timing labels are not universal formulation rules. Source tabs Topical | |||||
| OtherDaily moisturizer | 3% concentration | 1-2x daily | Preventive UseReference report | Continuous use - effects require ongoing application | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. “Up to 63%” is not a typical expected result. Pairing/timing labels are not universal formulation rules. Source tabs Topical | |||||
| OtherMulti-peptide serum | 3-5% with other peptides | 2x daily | Combined Peptide ProtocolReference report | Continuous use - effects require ongoing application | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. “Up to 63%” is not a typical expected result. Pairing/timing labels are not universal formulation rules. Source tabs Topical | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Topical
- Use period
- Continuous use - effects require ongoing application
- Break
- No cycling required - safe for long-term continuous use
Reported timing
After cleansing, before moisturizer
Side effects & safety
Short combined-product observation
No adverse effects were reported in 24 people over 28 days; that cannot rule out uncommon or long-term effects.
2Route boundary
Cosmetic patch findings do not establish safety for injection or for an arbitrary serum concentration.
2Local
Irritation, redness, burning, pigmentation changes or sensitivity.
Stop symptoms
Persistent irritation, allergy, worsening skin, eye irritation or vision changes.
Unknowns
Pregnancy/breastfeeding evidence insufficient; cosmetic mixture stability varies.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
11 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Retinol
Caution reportedIrritation potential.14
Reference report · Pep-Pedia label: Use CautionVitamin C
Caution reportedReference pH/stability concern.14
Reference report · Pep-Pedia label: Requires TimingAHA/BHA
Caution reportedIrritation/stability concerns.14
Reference report · Pep-Pedia label: Use CautionCopper peptides
Caution reportedSource cautions concurrent retinol.14
Reference report · Pep-Pedia label: Use CautionArgireline
Unverified pairingRelated mechanism; possibly redundant.14
Reference report · Pep-Pedia label: SynergisticLeuphasyl
Unverified pairingExperimental inhibition findings.14
Reference report · Pep-Pedia label: SynergisticGHK-Cu
Unverified pairingFormula-dependent pairing.14
Reference report · Pep-Pedia label: CompatibleHyaluronic acid
Unverified pairingHydration pairing.14
Reference report · Pep-Pedia label: SynergisticNiacinamide
Unverified pairingFormula-dependent pairing.14
Reference report · Pep-Pedia label: CompatibleMatrixyl
Unverified pairingUnproven combined benefit.14
Reference report · Pep-Pedia label: SynergisticOther peptides and medicines
Not establishedA controlled interaction assessment for this exact compound and formulation was not identified in the sources checked. Absence of interaction data is not evidence of compatibility.3
Research contextNo matching interactions. Try another name or filter.
Reconstitution
A product-specific preparation or sterility protocol has not been verified.3
Dilution
A concentration calculation cannot establish a suitable diluent, compatibility, storage interval, or sterility. No universal bacteriostatic-water volume is assigned.3
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Topical
The topical section discusses a finished serum or incorporation into a cosmetic base.
- Form
- Source describes a prepared product
- Reported parameters
- The source lists 3–10%, but does not clearly resolve raw peptide versus supplier premix concentration.
Do not equate a supplier blend percentage with pure peptide concentration.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceClear, colorless solutionReported appearancepH between 3.0-5.0Reported appearanceProper packagingReported appearanceGradual visible resultsReported variationConcentration verificationReported concernCloudy or discolored solutionReported concernStrong odor or unusual smell
14Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
No applicable mixing data
The available sources describe prepared products or do not establish a reconstitution method.14
Storage notes
14Solution at 4°C (refrigerated); powder at room temperature in cool, dark place
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Evidence limits
View findings →The peptide’s independent contribution was not isolated in the verified trial.2
2 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
Limited human dataSource context
“Up to 63%” is not a typical expected result. Pairing/timing labels are not universal formulation rules.
Compound identity & other names
SNAP-8 is acetyl octapeptide-3. A small human study tested it inside a multi-ingredient microneedle patch. Argireline, a different hexapeptide, is not automatically evidence for SNAP-8.
Other names: Acetyl octapeptide-3
Investigational; this profile does not establish an approved use.
Acetyl octapeptide-3; distinct from acetyl hexapeptide-8/Argireline214
Pep-Pedia identity record
8 amino acids · 1,075.16 Da
Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2Reference description; checked chemical identity takes precedence when available.14
How it may work
Proposed interference with SNAP-25/SNARE-mediated neurotransmitter release; skin delivery limits interpretation.14
Combined microneedle patch
The active patch improved measured skin outcomes and had no reported adverse effects. It also contained a vitamin-C derivative and cyclic lysophosphatidic acid, so SNAP-8’s contribution is unresolved.
2Research areas and evidence gaps
Wrinkle appearance: a combined cosmetic patch. Scope of investigation or explicitly identified community interest; not an established indication.2
- The peptide’s independent contribution was not isolated in the verified trial.
- The evidence does not validate the identity, purity or handling of a separately sourced research product.
Additional uses listed by Pep-Pedia
Wrinkles. Expression, forehead and crow’s-feet lines.14
Skin. Hydration, prevention and sensitive-area claims; formulation-specific evidence.14
Community reports Unvalidated
Pep-Pedia reports use in the research-peptide community. These reports are not clinical evidence.3
The percentage basis in Pep-Pedia’s 3–5% cosmetic table is not independently resolved; it may not represent pure active peptide. It is not a compounding formula.
Search coverage and review status
Additional primary or regulatory sources were checked. No further 2025–2026 exact-compound clinical outcome study was identified in this targeted search; this is not evidence that none exists.
- Checked
- 2026-10-12
- Search
- SNAP-8 acetyl octapeptide 2025 2026 trial; SNAP-8 10.5021/ad.23.136
- Catalog
- Pep-Pedia ↗ · 11 listed references retained
- Targeted search, not a systematic or exhaustive review.
- Retained bibliography entries marked Bibliography only have not been independently verified.
- Distinct URLs may refer to the same publication; component and formulation boundaries remain important.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
Number of responses to this question: not disclosed.
Effectiveness
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Would recommend
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
Number of responses to this question: not disclosed.
Source & limitations
The source displays “216 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term ActivitiesAbstract checked
AI-PREPARED SUMMARY
A 24-person 28-day trial compared a multi-ingredient microneedle patch with a hyaluronic-acid patch.
Pep-Pedia bibliography · Checked 2026-10-12
2Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term ActivitiesAbstract checked
AI-PREPARED SUMMARY
A 24-person 28-day trial compared a multi-ingredient microneedle patch with a hyaluronic-acid patch.
Combined microneedle patch
The active patch improved measured skin outcomes and had no reported adverse effects. It also contained a vitamin-C derivative and cyclic lysophosphatidic acid, so SNAP-8’s contribution is unresolved.
Additional research · Checked 2026-10-12
3Pep-Pedia: SNAP-8Community source checked
AI-PREPARED SUMMARY
Secondary community overview checked on 12 October 2026. Its practice tables and efficacy claims are not independently validated clinical guidance.
4Pintea, A., Manea, A., Pintea, C., et al. (2025). Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review. Biomolecules, 15(1), 88.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The review surveys skin-aging peptide mechanisms, including neurotransmitter modulation; it is not a direct controlled SNAP-8 efficacy trial.
Reported population / model
Review
Reported study details
Comprehensive peptide analysis · Anti-aging mechanisms
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Wang, Y., Wang, M., Xiao, S., Pan, P., Li, P., Huo, J. (2013). The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. American Journal of Clinical Dermatology, 14(2), 147-153.Argireline is a different hexapeptide, not SNAP-8 acetyl octapeptide-3.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The trial concerned Argireline, a related hexapeptide, with improved wrinkle measures; it cannot directly validate SNAP-8.
Reported population / model
Human
Reported study details
10% solution · 4 weeks · 60 Chinese subjects
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Argireline is a different hexapeptide, not SNAP-8 acetyl octapeptide-3.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Errante, F., Ledwón, P., Latajka, R., et al. (2020). Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Molecules, 25(9), 2090.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports SNARE-related inhibition in laboratory assays, including combinations; topical clinical outcomes require separate evidence.
Reported population / model
In vitro
Reported study details
1.5 mM concentration · Catecholamine release assay
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Ji, M., Lee, H.S., Kim, Y., et al. (2020). Method development for acetyl octapeptide-3 analysis by liquid chromatography-tandem mass spectrometry. Journal of Analytical Science and Technology, 11(1), 40.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The study developed an analytical assay for SNAP-8 in formulations and microneedle systems; quantification is not proof of anti-wrinkle efficacy.
Reported population / model
Analytical
Reported study details
Mass spectrometry · Microneedle patch quantification
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Blanes-Mira, C., Clemente, J., Jodas, G., et al. (2002). A synthetic hexapeptide (Argireline) with antiwrinkle activity. International Journal of Cosmetic Science, 24(5), 303-310.Argireline is a different hexapeptide, not SNAP-8 acetyl octapeptide-3.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The reported up-to-30% wrinkle-depth reduction concerns Argireline, not the longer SNAP-8 sequence.
Reported population / model
Human
Reported study details
10% O/W emulsion · 30 days · Skin topography analysis
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Argireline is a different hexapeptide, not SNAP-8 acetyl octapeptide-3.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Wang, Y., Wang, M., Xiao, S., Pan, P., Li, P., Huo, J. (2013). The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. American Journal of Clinical Dermatology, 14(2), 147-153.Argireline is a different hexapeptide, not SNAP-8 acetyl octapeptide-3.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
10Blanes-Mira, C., Clemente, J., Jodas, G., et al. (2002). A synthetic hexapeptide (Argireline) with antiwrinkle activity. International Journal of Cosmetic Science, 24(5), 303-310.Argireline is a different hexapeptide, not SNAP-8 acetyl octapeptide-3.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
11Errante, F., Ledwón, P., Latajka, R., et al. (2020). Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Molecules, 25(9), 2090.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
12Ji, M., Lee, H.S., Kim, Y., et al. (2020). Method development for acetyl octapeptide-3 analysis by liquid chromatography-tandem mass spectrometry. Journal of Analytical Science and Technology, 11(1), 40.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
13Pintea, A., Manea, A., Pintea, C., et al. (2025). Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review. Biomolecules, 15(1), 88.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
14Pep-Pedia: SNAP-8 — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12